STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer. Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and










